BACKGROUND: We studied the extent of neuroendocrine (NE) tumor cell differentiation and its relation to regressive changes in prostate cancer after 3-month hormonal treatment. METHODS:Radical prostatectomy specimens from 103 patients, randomized to 3-month neoadjuvant LH-RH-analogue treatment (neoadjuvant group) or to surgery alone (control group), were available for analysis. The effects of hormonal treatment in terms of positive surgical margins, the degree of histopathological changes, and tumor cell proliferation were evaluated in relation to NE-differentiation assessed with antibodies against chromogranin A (CGA). RESULTS: Both the number of CGA-positive cells/cm(2) (P < 0.003) and the proportion of NE-positive tumors (P = 0.07) were greater in the neoadjuvant group than in the control group. No correlation existed between NE-differentiation and the effects of the neoadjuvant hormonal treatment; nor did NE-differentiation correlate to the decrease in serum PSA. CONCLUSIONS: Neuroendocrine differentiation in prostate cancer increases after 3 months of neoadjuvant hormonal treatment but does not correlate to the effects of hormonal treatment. Copyright 2000 Wiley-Liss, Inc.
RCT Entities:
BACKGROUND: We studied the extent of neuroendocrine (NE) tumor cell differentiation and its relation to regressive changes in prostate cancer after 3-month hormonal treatment. METHODS: Radical prostatectomy specimens from 103 patients, randomized to 3-month neoadjuvant LH-RH-analogue treatment (neoadjuvant group) or to surgery alone (control group), were available for analysis. The effects of hormonal treatment in terms of positive surgical margins, the degree of histopathological changes, and tumor cell proliferation were evaluated in relation to NE-differentiation assessed with antibodies against chromogranin A (CGA). RESULTS: Both the number of CGA-positive cells/cm(2) (P < 0.003) and the proportion of NE-positive tumors (P = 0.07) were greater in the neoadjuvant group than in the control group. No correlation existed between NE-differentiation and the effects of the neoadjuvant hormonal treatment; nor did NE-differentiation correlate to the decrease in serum PSA. CONCLUSIONS: Neuroendocrine differentiation in prostate cancer increases after 3 months of neoadjuvant hormonal treatment but does not correlate to the effects of hormonal treatment. Copyright 2000 Wiley-Liss, Inc.
Authors: Jiaoti Huang; Jorge L Yao; Li Zhang; Patricia A Bourne; Andrew M Quinn; P Anthony di Sant'Agnese; Jay E Reeder Journal: Am J Pathol Date: 2005-06 Impact factor: 4.307
Authors: S S Jeetle; G Fisher; Z H Yang; E Stankiewicz; H Møller; C S Cooper; J Cuzick; D M Berney Journal: Virchows Arch Date: 2012-07-06 Impact factor: 4.064
Authors: Lei Wang; Melissa J L Bonorden; Guang-xun Li; Hyo-Jeong Lee; Hongbo Hu; Yong Zhang; Joshua D Liao; Margot P Cleary; Junxuan Lü Journal: Cancer Prev Res (Phila) Date: 2009-04-28
Authors: Wendy J Huss; Danny R Gray; Keyvan Tavakoli; Meghan E Marmillion; Lori E Durham; Mac A Johnson; Norman M Greenberg; Gary J Smith Journal: Neoplasia Date: 2007-11 Impact factor: 5.715
Authors: Shivendra V Singh; Anna A Powolny; Silvia D Stan; Dong Xiao; Julie A Arlotti; Renaud Warin; Eun-Ryeong Hahm; Stanley W Marynowski; Ajay Bommareddy; Douglas M Potter; Rajiv Dhir Journal: Cancer Res Date: 2008-11-15 Impact factor: 12.701
Authors: David S Priemer; Rodolfo Montironi; Lisha Wang; Sean R Williamson; Antonio Lopez-Beltran; Liang Cheng Journal: Endocr Pathol Date: 2016-06 Impact factor: 3.943